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Objective: To understand the mechanisms and epidemiology of resistance to  oxyiminocephalosporins in  Escherichia 
coli over a 2-year period in  a French hospital. 
Methods: Forty-four strains, resistant or intermediately resistant t o  one of the oxyiminocephalosporins or aztreonam, 
were collected from 35 patients. MIC determinations were carried out for the 44 isolates using a panel of p-lactam 
antibiotics, and characterization of the P-lactamases they produced by isoelectric focusing and catalytic activity measure- 
ment. Extended-spectrum 0-lactamase production was studied by use of the double disk diffusion test. Conjugation 
experiments were used to  search for plasmidic cephalosporinase. An epidemiologic study was then performed, by use 
of molecular typing of the strains with an ERIC-PCR method and a case-control analysis. 
Results: Less than 1% of all the E. cob isolates at our hospital showed decreased susceptibility t o  oxyimino- 
cephalosporins. Only three of the 44 isolates showed synergy between clavulanate and a third-generation cephalosporin 
and produced an extended-spectrum p-lactamase. For the other strains, a p-lactamase with a highly basic isoelectric 
point was detected. Spectrophotometric measures confirmed that most of these isolates were AmpC hyper-producers. 
No plasmidic cephalosporinase could be detected by conjugation experiments. Molecular typing showed all isolates to  
be different, except for two strains isolated in two patients of the same hospital unit, and for the repeated isolates of 
some patients. When 20 case patients were compared to  40 randomly selected control patients, prior receipt of an 
antimicrobial and more specifically of a p-lactam agent was significantly associated with case patients. 
Conclusions: Although it appears to  be very rare, the resistance to  broad-spectrum cephalosporins needs our 
attention, because of the high frequency of E. coli infections and p-lactam use in their treatment. 
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INTRODUCTION 
The emergence of resistance to antimicrobial agents is 
becoming a major public-health problem worldwide, 
especially in hospital-acquired infections. Eschericliia coli 
is among the most important human pathogens, judged 
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by the number and the diversity of community- or 
hospital-acquired infections it causes. The emergence 
in this organism of resistance t o  the antimicrobials 
commonly used to treat these infections, such as 
p-lactam agents, especially oxyiminocephalosporins, 
would represent a public-health hazard. Therefore, 
emergence of resistance in this organism should be 
investigated promptly in order to prevent the selection 
and/or spread of these organisms. 
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Resistance to oxyiminocephalosporins is rare in 
Escherichia coli, representing less than 2% of the isolates 
in most studies [l-31. The occurrence at our institution 
of 44 cases of infection caused by Escherichia coli strains 
showing either decreased susceptibility or resistance to 
third-generation cephalosporins (representing 0.7% of 
all Eschevichia coli isolates) led us to analyze the bacterial 
mechanism of resistance, and to conduct an epidemio- 
logic study to determine the risk factors for the 
emergence and/or spread of such strains. 
MATERIALS AND METHODS 
Bacterial strains 
From January 1995 to December 1996, 44 strains of 
Eschericlzia coli intermediately resistant or resistant to 
oxyiminocephalosporins (cefotaxime or ceftazidime) 
and aztreonam according to the rapid ATBE system 
(bioM6rieux SA, Marcy-l’Etoile, France) were isolated 
from 35 patients from different units at Nantes 
Hospital: 26 from urine, five from blood, one from 
stools, one from placenta and the others from pus of 
different origins. 
Susceptibility tests 
Susceptibility to p-lactams was determined by the disk 
diffusion method (Sanofi Diagnostic Pasteur, Marnes la 
Coquette, France) with Mueller-Hinton (MH) agar 
(Difco Laboratories, Detroit, MI, USA), supplemented 
or not with 2 mg/L of clavulanic acid or 4 mg/L of 
tazobactam, according to the recommendations of the 
‘Comiti. de l’antibiogramme de la Socikti. FranGaise de 
Microbiologie’ (CA-SFM) [4]. 
Minimal inhibitory concentrations (MICs) were 
determined by serial two-fold dilution tests in M H  
agar. Inocula of lo4 CFU/spot from an 18-h culture in 
M H  broth were applied with a Steers multiple-inoculum 
replicator. MICs of third-generation cephalosporins 
were determined individually or in combination with 
clavulanic acid (2 mg/L) or tazobactam (4 mg/L). 
Escherichia coli ATCC 25922 was used as a control strain. 
A synergy test between a third-generation cephalo- 
sporin disk and a coamoxiclav disk was used to detect 
the presence of an extended-spectrum p-lactamase 
(ESBL). Cefotaxime, ceftazidime and aztreonam disks 
were placed 30 mm from the coamoxiclav disk (center 
to center), according to the CA-SFM guidelines [4]. 
The antibiotics were obtained as powders of 
certified potency: amoxycillin and ticarcillin (SmithKline 
Beecham, Nanterre, France), piperacillin (Lederli., 
Paris, France), cephalothin (Lilly France SA, Saint- 
Claid, France), cefoxitin and imipenem (Merck Sharpe 
&. Dohme-Chibret, Paris, France), cefuroxime and 
ceftazidime (Glaxo Wellcome, Paris, France), cefixirne 
(Rhhe-Poulenc Rorer, Montraige, France), cefo- 
taxime (Roussel, Paris, France), aztreonam (Sanofi 
Winthrop, Gentilly, France), cefepime (Bristol-Myers 
Squibb, Paris, France), cefotetan (Zeneca Pharma, 
Cergy, France). Clavulanic acid was supplied by 
SmithKline Beecham laboratories and tazobactam by 
Lederle laboratories. 
Conjugation experiments 
M H  broth cultures of the donor and the recipient 
strain, Escherichia coli K12 rifarnpin-resistant J53-2, 
were mixed 1:4 for 16 h at 37°C [5]. Transconjugant 
clones were selected on M H  agar containing amoxy- 
cillin (100 mg/L) and rifampin (300 mg/L). 
P-Lactamase studies 
p- Lactamase extraction 
After 18 h of culture in trypticase soy broth (bioM6rieux 
SA), bacterial pellets were obtained by 30 min of centri- 
fugation at 10 000 g. After washing and resuspension in 
distilled water, bacteria were submitted to sonication in 
a Branson Sonifier 250 to disrupt bacterial cell walls 
(intermittent exposure of 5 X 30 s). After centrifugation, 
the supernatant contained the crude p-lactamase extract. 
lsoelectric focusing (IEF) 
IEF was performed according to the method of 
Matthew et al [6] by using an 8% acrylamide/ 
bisacrylamide (19:l) gel in the LKB multiphor system 
(LKB Pharmacia, Uppsala, Sweden). The pH range 
covered by the ampholytes was either large (4-10) to 
detect all kinds of p-lactamases, or narrow: 8-10 to 
characterize AmpC cephalosporinase, and 4-6.5 to 
characterize TEM-type p-lactamases. The following 
enzymes were used as references for determination of 
isoelectric point (PI): IRT-2 (pI=5.2), CARE-1 
(pI=5.3), TEM-1 (pI=5.4), TEM-2 (pI=5.6), 
CARB-3 (pI=5.75), TEM-3 (PI= 6.3), SHV-I-like 
(pI=7.1), SHV-1 (pI=7.6). Escherichia coli K12 p- 
lactamase was used as a reference for highly basic 
isoelectric points. An iodine-starch agar gel was used 
to visualize the P-lactamase bands [7]. 
Assay of cephalosporinase 
Cephalosporinase activity was assayed by a spectro- 
photometric method using a Beckman D U  7500 
spectrophotometer. The decrease in absorbance at 262 
nm was measured, using cephalothin (200 pM) as a 
substrate in 50 mM phosphate buffer, pH 7.4. Results 
were expressed as nmol/min per mg of protein. 
Proteins were determined by the pyrogallol red- 
molybdate method [8]. Cephalosporinase activity was 
measured only for strains that produced a single 
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p-lactamase with a PI >9.0. The @-lactamase extracted 
from Esclievichia coli K12 was used as a control. 
Characterization of the blaTEM genes of ESBL-producing 
strains 
Plasmidic DNA was extracted from the three ESBL- 
producing strains and their respective transconjugants 
by alkaline lysis [9]. Three sets of primers were 
chosen in the blaTEM sequence [lo]. The 
sequences of the primers were as follows: 
TEM A 148 (GTATCC GCTCATGAGACAAT) 167 and 
T E M c  ~c,~(TGATAACACTGCGGCCAACT)~I 1 and 
TEMr, 8w(ATAAACCAGCCAGCCGGAAG)875, and 
TEME R?~(GACTGGATGGAGGCGGAT)~~~ and 
these give PCR products of, respectively, 544, 302 and 
238 bp. The three PCR amplifications were performed 
in a Perkin-Elmer 480 DNA thermal cycler (Perkin- 
Elmer, Applied Biosystems, Cergy-Pontoise, France). 
The P C R  reaction took place in a final volume of 
50 p L  containing 10 mM Tris-HC1, p H  8.3, 50 mM 
KCl, 3.5 mM MgC12, 200 p M  of each nucleotide, 
0.5 pM of each primer, 3.5 units of Taq DNA poly- 
merase (Gibco BRL, Life Technologies SARL, Cergy 
Pontoise, France) and 10 ng of target DNA. A 1 min 
30 s denaturation at  94°C was performed, followed by 
30 cycles of PCR, with the annealing temperatures 
depending on the primer pairs, and a final extension 
step of 73°C for 1Umin. The PCR products were 
purified and sequenced according to the dideoxy- 
nucleotide method [ l l ] .  
T E M B  h92(  GATCAAGGC GAGTTACATGA) 673, 
T E M F  loh5(CAATGCTTAATCAGTGAGGC)iu46; 
Molecular typing by repetitive element sequence-based 
PCR with Enterobacterial Repetitive lntergenic Consensus 
(ERIC II) primer 
The oligonucleotide primer ERIC I1 AAG TAA GTG 
ACT GGG GTG AGC G [12], designed from the 
central inverted repeat of the ERIC sequence, located 
in extragenic regions of various enterobacteria, was 
used for amplification of variable-length ~-egions 
between these interspersed repetitive elements. Amplifi- 
cation reactions were performed in a volume of 50 pL 
and contained 10 mM Tris-HC1, pH 8.3, 50 mM KC1, 
200 pM of each deoxynucleotide, 0.5 p M  of each 
primer, 3 mM MgC12, 3.5 U of Taq polymerase (Gibco 
BRL, Life Technologies SARL) and 10 ng of target 
DNA. After denaturation for 1 min and 30 s at  94"C, 
the amplification mix was submitted to 44 cycles of 15 
s of denaturation at 94"C, 15 s of annealing at  35OC 
and 70 s of extension at 72"C, with a final extension 
of 7 min at 72°C. Reactions took place in an auto- 
mated Perkin-Elmer 480 DNA thermal cycler. Each 
experiment included a blank without DNA. Fifteen 
microliters of the P C R  product was size fractionated by 
electrophoresis in a horizontal 1.5% agarose gel for 2 h 
at 130 V in TBE buffer (Tris 89 mM, borate 89 mM, 
EDTA 2 mM, pH 8), stained with ethidium bromide 
and visualized under UV light. Analysis of results was 
done with the gel compar software (Applied Maths, 
Kortijk, Belgium). 
Case-control study 
A case-control study was performed to assess potential 
risk factors associated with infections caused by 
Eschericlzia coli with decreased susceptibility or resistance 
to third-generation cephalosporins. Twenty case 
patients were compared with two different groups of 
control patients. The first group included 40 control 
patients infected with a strain of Esclierichiu coli 
susceptible to all p-lactam agents. The second group 
included 40 patients who had developed an infection 
caused by Eschevicliia coli strains presenting a peni- 
cillinase phenotype. The following data were abstracted 
from the medical records of case and control patients: 
age, sex, unit of hospitalization, dates of admission and 
discharge, nature and date of collection of the specimen 
positive for Esclievichia coli, exposure to invasive devices 
and surgical procedure, underlying diseases, immuno- 
suppressive therapy, history of infectious diseases and 
hospitalizations and prior receipt of antimicrobial 
therapy. Data were analyzed with the Epi-Info software 
(Version 6, Centers for Disease Control and 
Prevention, Atlanta, Georgia, USA). Fischer's two- 
tailed exact test and Student's t-test were used for the 
significance of association. 
RESULTS 
Over a 2-year period, 44 strains of Esclzerichia coli with 
reduced susceptibility to oxyiminocephalosporins were 
isolated from 35 patients hospitalized in different units 
at Nantes hospital. The predominance of urinary tract 
isolates (59%) was proportional to the frequency of 
Eschevicliia coli in urine infections. The sex ratio 
(male/female) of the patients was 1:3.4. In six of the 35 
patients, more than one strain was isolated. In one 
patient, the same strain was isolated from two different 
sites (urine and biliary secretion). In another patient, 
we noted an increase of the resistance to oxyimino- 
cephalosporins of two strains isolated 40 days apart 
(MIC of ceftazidime = 32 versus 4 mg/L). 
Among the 44 strains studied, only three presented 
a positive synergy test between co-amoxiclav and a 
third-generation cephalosporin. The activity of the 
corresponding enzymes was strongly inhibited by 
P-lactamase inhibitors. The MICs of several p-lactams 
for these three isolates and the isoelectric points of the 
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Table 1 Characterization of the three ESBL-producing strains: MICs of several p-lactams, isoelectric points of the 
corresponding P-lactamases, and positions where mutations were detected compared with TEM-1 p-lactamase 
Strain 401 Strain 3007 Strain 10399 
Alone + CA Alone + CA Alone +CA 
MICs 
Amoxycillin 
Ticarcillin 
Piperacillin 
Cephalothin 
Cefoxitin 
Cefuroxime 
Cefixime 
Cefotaxime 
Ceftazidime 
Aztreonam 
Cefotetan 
Cefepime 
Imipenem 
PI of the P-lactamase 
Mutations detected 
at position” 
37 
102 
151 
162 
236 
4096 
4096 
128 
256 
4 
8 
2 
<0.25 
128 
16 
1 
1 
0.125 
5.6 
Glu-Lys 
Arg-Ser 
16 
32 
ND 
ND 
ND 
ND 
ND 
<0.25 
I 
<0.25 
0.5 
ND 
ND 
4096 
4096 
256 
256 
4 
32 
2 
8 
16 
8 
1 
0.125 
3 
I 
6.4 
16 
64 
ND 
ND 
ND 
ND 
ND 
<0.25 
0.5 
<0.25 
0.25 
ND 
ND 
4096 16 
4096 32 
128 ND 
256 ND 
8 ND 
8 ND 
2 ND 
<0.25 <0.25 
16 1 
1 <0.25 
1 0.25 
0.5 ND 
0.25 ND 
5.3 
Gln-Lys 
Glu-Lys 
His-Arg 
Arg-Ser 
Gly-Ser 
CA, clavulanic acid (2 mg/L); ND, not determined. 
5utcIiffe numbering. 
Table 2 MICs of the 41 non-ESBL-producing isolates 
MICs (mg/L) 
Compound Range Modal 50% 90% 
Amoxycillin 256 to >lo24 2 1024 512 21024 
Amoxycibn/clavulanic acid 256 to >lo24 5 12-1024 512 2 1024 
Ticarcillin 16 to >lo24 32 128 2 1024 
Ticarcillin/clavulanic acid’ 16 to >lo24 32 64 256 
Piperacillin 4-5 12 8 16 256 
Cefoxitin 16-256 32 32 256 
Cefuroxime 16 to >lo24 64 64 256 
Cefixime 32 to >I024 64 64 1024 
Cefotaxime 0.5-16 1 1 16 
Cefotaxime/clavulanic acida 0.5-16 1 1 16 
Cefotaxinie/tazobactamb 0.5-16 1 1 16 
Ceftazidime 2-64 4 8 32 
Ceftazidime/clavulacic acid’ 2-32 4 4 32 
Ceftazidime/tazobactamb 1-32 4 4 32 
Aztreonam 2-16 4 4 16 
Aztreonam/clavulanic acid” 2-16 4 4 16 
Aztreonam/tazobactamb 0.5-16 2 I 16 
Cefotetan 2-64 4 4 64 
Cefotetaidclavulanic acid” 1-64 4 4 64 
Cefotetan/tazobactamb 0.5-32 1 I 32 
Cefepime 0.06-0. 5 0.06 0.06 0.25 
Imipenem 0.125-0.5 0.25 0.25 0.5 
a2 mg/L. 
b4 mg/L. 
Cephalothin 256 to >lo24 21024 21024 2 1024 
3 
3 
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Figure 1 (A) Analytic isoelectric focusing (pH range 4-1 0) of the P-lactamases extracted from six third-generation resistant 
Escherichia colt strains (lanes 1-6), Escherirhia coli K12 (lane 7) and p453 (pI=7.6) (lane 8). (B) Analytic isoelectric focusing 
(pH range 8-10) of the P-lactamases extracted from Escherirhia rali K l ?  (lane l), and six of the third-generation 
cephalosporin-resistant isolates (lanes 2-7). 
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Table 3 Isoelectric points (PI) of the p-lactamases produced by the 
44 third-generation resistant isolates of Escherichia coli 
~~ ~ 
PI Number of isolates 
5.3 
5.6 
6.4 
>9.0 
>Y.0+5.4 
>9.0+5.2 
1 
1 
1 
26 
12 
3 
P-lactamases they produced are presented in Table 1. 
The corresponding blaTEM genes were sequenced 
after PCR using three different sets ofprimers, showing 
that the enzymes were different from one another, and 
differed from TEM-1 by one to four point mutations 
(Table 1). According to the literature and the databanks, 
these P-lactamases could correspond, respectively, to 
TEM-26, TEM-21 and TEM-12 [13]. 
For the other 41 strains, no significant decrease of 
the oxyiminocephalosporin MICs could be observed in 
the presence of P-lactamase inhibitors (no more than a 
two-fold decrease in the presence of clavulanate). No 
ESBL could be detected by the double &sk diffusion 
test. The suspected mechanism was hyperproduction of 
chromosomal cephalosporinase. They were more resis- 
tant to cephamycins such as cefoxitin or cefotetan 
(Table 2) than the three strains producing an ESBL. The 
MICs of cefotaxime were always lower than those of 
ceftazidime and aztreonam. Cefepime and imipenem 
conserved good activity against these strains. However, 
for the most resistant strains, the MICs of imipenem 
and cefepime were 5-10-fold higher than those for the 
susceptible strains. 
IEF performed on crude P-lactamase extracts 
obtained from these 41 strains revealed a highly basic 
band that developed rapidly, corresponding to AmpC 
cephalosporinase. All these basic p-lactamases presented 
the same isoelectric point (Figure 1A). In a pH 4-10 
gradient, it seemed very close to that of the cephalo- 
sporinase extracted from Escherichia coli K12. However, 
by using a narrow gradient (PH 8-10), it was possible 
to see that the isoelectric point was slightly higher for 
the patients’ P-lactamase extracts than for the reference 
enzyme (Figure 1B). 
Twelve of the 41 cephalosporinase hyperproducers 
also produced a PI 5.4 TEM-1 P-lactamase, and three 
isolates from the same patient produced an enzyme co- 
migrating with the 5.2 reference enzyme (Table 3) .  
Sequencing of the corresponding 6laTEM gene 
Table 4 Cephalosporinase activity for 21 isolates producing a single P-lactamase with a pI>9.0, compared with 
Erckerickia coli K12 
MICs (mg/L) 
Cephalosporinase 
Isolate Cephalothn Cefoxitin Ceftazidime Cefotaxime Cefepime activity (nmol/min per mg) 
E. coli K12 
1498 
725 
4276 
5271 
1378 
3973 
4140 
7442 
6408 
7000 
979 
1372 
3917 
5299 
1139 
6019 
7474 
7791 
8197 
4686 
2328 
4153 
4 
256 
512 
512 
1024 
1024 
1024 
1024 
1024 
1024 
2048 
1024 
1024 
1024 
2048 
1034 
2048 
1024 
2048 
1024 
2048 
2048 
1048 
2 
16 
16 
32 
64 
32 
32 
32 
32 
32 
32 
32 
32 
32 
64 
64 
64 
32 
128 
128 
64 
128 
512 
0.125 
2 
4 
4 
2 
4 
4 
4 
4 
4 
4 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
32 
64 
0.06 
0.5 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
4 
32 
<0.015 
0.03 
0.03 
0.03 
0.03 
0.03 
0.06 
0.03 
0.06 
0.03 
0.03 
0.03 
0.03 
0.03 
0.06 
0.03 
0.06 
0.06 
0.06 
0.06 
0.06 
0.25 
0.5 
ND 
508 
458 
657 
672 
435 
579 
734 
463 
917 
341 
474 
490 
453 
404 
851 
498 
707 
1442 
1561 
1537 
1522 
3174 
ND, not detectable. 
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Table 5 MICs and b-lactamase isoelectric points of the two strains isolated from the same patient with a 40-day interval 
Strain 9900 (pl>9.0) Strain 10831 (pl>9.0) 
P-Lactani Alone + CA" Alone +CA' 
Amoxycilliii 512 512 1024 1024 
Ticarcillin 16 16 4096 2048 
Piperacillin 4 ND 16 ND 
Cephalothiri 756 "1 256 ND 
Cefoxitin 16 ND 16 N1) 
Cefuroxime 32 N 1) 128 ND 
Cefotaxirne 0.5 0.5 I 2 
Cefiazidirnt. 4 2 32 32 
Aztreonam 16 8 
Cefotetan 2 L 16 H 
CefEiine 32 ND 128 ND 
3 
3 3 
7 
I 
Cefepiine 0.03 ND 0.25 ND 
lmipcneni 0.25 ND 0.5 NII 
Crphalosporinase activity 
(ntnol/min per ing) 539 < 100 
"2 tng/L. 
ND, not determined; CA, clavulanic acid. 
Table 6 Results of the case-control study 
First control group" Second control grouph 
Variables P-value OR 95% CI P-value OK Y53.n CI 
- Age 0.29 - 0.65 
Sex 0.23 0.5 0.13-1.8 0.7 0.8 0.7-0.8 
- - 
~ - Unit of hospitalization 0.42 0.62 - - 
Duratioii of hospitalization 
Origin of infection 
Site of infection 
Presence of urinary indwelling 
Prior receipt of antiniicrobials 
Prior receipt of p-lactams 
Immunosuppressive therapy 
History of neoplasia 
Recent history of surgery 
History of urinary tract disease 
History of hospitalization 
0.41 
1 
0.35 
0.002' 
0.07' 
0.65 
0.05 
0.32 
0.18 
catheter 0.8 
0.06 
- 
1 
1.1 
6 
4.5 
1.3 
3.8 
2.7 
1.7 
- 
7 3  
I.I 
- 
0.3-3.6 
0.3-4.7 
1.6-24 
1.1-17.8 
0.3-5.6 
0.8-20 
0.8-9.9 
0.5-6.4 
0.6-8.7 
- 
0.20 
0.41 
1 
0 . 0 2 c  
0.12 
0.09 
0.09 
1 
0.18 
0.8-1 
0.08 
- 
0.9 
1 
3.5 
2.9 
3 
3 
2.5 
1 
- 
7 3  *_.. 
- 
0.2-(1.9 
- 
0.2-4 
1.1-1 1 
0.8-10.4 
0.7-14 
0.6-4.1 
0.7-8.8 
0.3-3.5 
0.6-8.8 
OR, odds ratio; 95% CI, confidence interval 95%. 
'Patients infected with a strain susceptible to all p-lactams. 
"Patients infected with a strain with a penicillinase phenotypc. 
'Statistically significant association (p<0.05). 
revealed a point mutation at  position 929 [lo], leading 
to an Arg+Ser substitution at position 241, described 
in IRT-2 P-lactamase [14]. Without IEF, it is impossible 
to suspect the presence of such an enzyme when it is 
associated with high-level production of cephalo- 
sporinase. No TEM-2 or OXA-1 enzymes were 
detected. 
Cephalosporinase activity was measured in the 
strains that produced only .4mpC 0-lactamase by 
monitoring the rate of hydrolysis of cephalothin. 
The  results are presented in Table 1 and confirm 
that most of these strains were ,4mnpC P-lactaniase 
hyperproducers and that the level of enzyme 
production is well correlated with the MICs 
observed. 
Except for the ESBL-producing isolates, no trans- 
fer of the oxyiniinocephalosporin resistance could be 
obtained by conjugation experiments. 
The molecular typing of the isolates showed that 
all patients were infected with organisms which differed 
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from one another, with the exception of two strains 
isolated 10 days apart from two patients hospitalized in 
the same hospital unit. O n  the other hand, strains 
isolated from the same patients were always identical, 
including the two strains from one patient showing an 
increase in the level of resistance to third-generation 
cephalosporins (Table 5) 
By univaridte analysis, case patients were more 
likely than control patients from both groups to have 
received prior antimicrobial therapy. When the type of 
antimicrobial use was analyzed, prior receipt of any p- 
lactam agent was statistically significantly associated 
with case patients when they were compared to the first 
group of control patients. The association was weaker 
when case patients were compared to the second group 
of control patients (Table 6). 
DISCUSSION 
Resistance to p-lactams in Escherichia coli, which has 
considerably increased in the last 30 years, is usually due 
to the production of TEM-1, or, less frequently TEM- 
2 P-lactamase, representing at least 30-500/0 of the 
Escherichia coli isolates in France [ l ,  151. Many strains 
produce large amounts of TEM-1, limiting the action 
of P-lactamase inhibitors [16]. Furthermore, since the 
beginning of the 1990s, inhibitor-resistant TEM (IRT) 
P-lactamases [ 171 have been described. Thus, third- 
generation cephalosporins that are not hydrolyzed by 
TEM-1 or IRT p-lactamases still constitute one of the 
best treatments for severe EschPvichia coli infections. 
Resistance to oxyiminocephalosporins is rare in 
Escherichia coli and is most often linked to the pro- 
duction of class A ESBLs [18]. In 1995-96, only three 
strains producing this kind of p-lactamase were isolated 
at our hospital from three sporadic cases of infection in 
patients hospitalized in three different hospital units. 
The strains presented different resistance patterns. The 
isoelectric points of the p-lactamases were different. 
The molecular typing patterns and sequencing of the 
blaTEM genes confirmed that they were different. 
The other group, quantitatively more important, 
included 4 1 isolates showing decreased susceptibility to 
third-generation cephalosporins that was not corrected 
by P-lactamase inhibitors. An increase in all p-lactani 
MICs was observed. Among the third-generation 
cephalosporins, the MICs of ceftazidime and aztreonam 
were higher than those of cefotaxime. This mechanism 
may be difficult to detect if cefotaxime is used instead 
of ceftazidime in the agar diffusion method. 
Although descriptions of plasmidic cephalo- 
sporinases are more and more frequent [19-211, we 
did not observe any transfer of the third-generation 
cephalosporin resistance for our isolates. The most 
likely hypothesis is the hyperproduction of AmpC 
cephalosporinase, confirmed by the presence of a 
rapidly appearing PI >9.0 band on IEF. The difference 
in PI of the Eschericltia coli K12 P-lactamase suggested 
amino acid mutations in the AmpC P-lactamase, but we 
do not know if they contribute to the high level of 
resistance. 
Esclzerichia coli cephalosporinase does not struc- 
turally differ from the other Enterobacteriaceae 
cephalosporinases [22], but its genetic organization is 
different, with deletion of regulatory regions, leading 
to low-level constitutive expression, usually without 
clinical expression. The overproduction of this cephalo- 
sporinase can be due to either promoter mutations 
[23-251 or to gene amplification on the bacterial 
chomosome [26,27]. Other mechanisms, such as 
variation in the stability of mRNA or in the efficiency 
of translation of mRNA to proteins, could be involved. 
This hyperproduction usually leads to resistance to 
amoxycillin, even combined with p-lactamase inhibi- 
tors, to first- and second-generation cephalosporins, 
but much more rarely to third-generation cephalo- 
sporins. The high level of resistance observed for some 
isolates in our study (MIC of ceftazidime=64 mg/L) 
leads to the hypothesis that another mechanism could 
be involved, such as loss of permeability due to porin 
mutations. Alterations of outer-membrane proteins 
have been proven to be necessary for high-level 
resistance to p-lactams in Escherichia coli [28-301. In 
fact, it has been recently shown that clinical Escherichia 
coli isolates hyperproducing AmpC 0-lactamase and 
presenting high-level resistance to oxyiminocephalo- 
sporins were OmpF deficient [31]. 
The epidemiologic study, using molecular typing 
of the third-generation cephalosporin-resistant strains, 
enabled us to notice the absence of epidemic strains. 
O n  the other hand, isolates from the same patient, 
taken several months apart, showed the same molecular 
patterns. Therefore, these strains appear to be difficult 
to eradicate. Their sporadic and sometimes repeated 
emergence suggests that they persist in the patient 
environment, probably in the endogenous flora. It 
could be hypothesized that p-lactam treatment at usual 
dosage, although sufficient to provide apparently good 
clinical efficacy, could be insufficient for eradication 
of the organisms. Consequently, the in vitro detection 
of this resistance pattern appears to be especially 
important, and it is particularly worrying to notice that 
it needed ceftazidime, rather than cefotaxime, which is 
usually used for p-lactam susceptibility testing. Thus, 
misinformation about this resistance pattern, leading to 
inappropriate antibiotic treatment, could result in the 
persistence of such strains. These data are in agreement 
with the results of the case-control study, showing prior 
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p-lactam antibiotic use to be a risk factor for the 
emergence of resistant strains. 
O n  the other hand, the sporadic occurrence of 
these strains was also in agreement with the hypothesis 
of a chromosome-encoded rather than a plasmid- 
encoded mechanism, based on the results of the 
conjugation experiments and p-lactamase analysis. 
Unlike strains with plasmid-encoded third-generation 
cephalosporin resistance, our strains did not seem to 
spread widely. Unlike the strains of Erztero6actev or 
Serratia that produced high levels of derepressed 
chromosome-encoded cephalosporinase, the strains we 
described showed moderate increases in oxyimino- 
cephalosporin MICs. These characteristics probably 
limit the risk of their emergence at present. 
The emergence of third-generation cephalosporin 
resistance during p-lactam therapy has been frequently 
described for inducible cephalosporinase-producing 
bacteria such as Ewterobacter or Servatiu [32], but 
exceptionally for Esclierichia coli. However, Aubert et a1 
[33] described the emergence of a cephalosporinase- 
hyperproducing strain from a susceptible Escherichia coli 
isolate, from a patient treated with the amoxycillin- 
clavulanate association. In our study, we noticed an 
increase in the level of ceftazidime resistance for two 
isolates of a patient with peritoneal infection, treated 
with imipeneni for 1 month and with ticarcillin- 
clavulanate for 2 weeks. In this case, the prolonged P- 
lactam treatment combined with the limited ability of 
antibiotics to diffuse in the deep infection site, could be 
responsible for the emergence of a more resistant strain. 
Surprisingly, the specific cephalosporinase activity was 
decreased in the second strain, so another mechanism 
is needed to explain the high level of resistance to 
o-xyiniinocephalosporins. 
Complementary studies are in progress to investi- 
gate mutations in the promoter or structural gene of 
AmpC P-lactamase of the reported strains, and possible 
additional mechanisms such as loss of permeability. 
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